German biopharmaceuticals contract development and manufacturing organization Rentschler Biopharma is extending and deepening its existing collaboration in Japan with Summit Pharmaceuticals International (SPI), a wholly owned subsidiary of Sumitomo.
Outsourcing product development and manufacturing has become for many pharmaceutical and biotech companies a strategic activity and an integral part of their business model.
The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021.
With this acquisition, Olon said it has successfully finalized its three-year development plan and will now move to its next target, which is to play an important role in manufacturing biologics APIs.
Cerbios has appointed Francesca Scarpitta as director of the company’s high potency active ingredients (HPAIs) production units.
Lugano, Switzerland-based chemical and biological API manufacturer Cerbios announced that its board of directors has approved the installation of a new production line in its building dedicated for high potency active ingredients (HPAIs).
